For example, bosutinib, dasatinib, and ponatinib are SRC/multikinase inhibitors that are approved by the FDA for the treatment of chronic myelogenous leukemia (Chen et al., 2015). The gene discussed is SRC; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.